Zeltiq raises $25M for fat-reduction tech

California-based Zeltiq has raised $25 million in Series D funding with the help of lead investor Aisling Capital.  Since being formed in 2005, Zeltiq has raised approximately $50 million. The devicemaker is developing non-invasive fat reduction technology, which uses a method called Cryolipolysis (the use of precisely controlled cooling to remove fat) to kill fat cells only. The company claims its method is safer, more effective and more comfortable for patients than other fat reduction options.

"Zeltiq is making an impressive start and on the road to creating a game-changing innovation in the aesthetic field. No technology we have seen better combines efficacy, safety, and patient comfort in an entirely non-invasive procedure as does Zeltiq. We look forward to a great collaboration with our fellow investors, Gordie, and the entire Zeltiq team," Dr. Andrew Schiff at Aisling says in a statement,

"The strong investment commitment and relationship that Dr. Schiff and the Aisling team bring to the table, combined with the continuing confidence from our original investors, enables us to scale up globally and execute against our plan," says Gordie Nye, President and CEO of Zeltiq.

- here's Zeltiq's release

ALSO: Anulex Technologies, amedical device manufacturer focusing on soft tissue Preservation & Anular Repair products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. Anulex release

PLUS: EarlySense has closed a $13 million third financing round led by Pitango Venture Capital. The company's lead product, the EverOn, is a contact-free patient supervision system installed underneath a hospital bed mattress. EarlySense release

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.